BPHL

Across TCGA pan-cancer cohorts, BPHL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BPHL data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BPHL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BPHL expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where BPHL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.886	.002	22	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
LUAD	DFS	Tertile	All	0.496	0.908	.001	10	view →
UCEC	OS	Tertile	All	0.912	1.000	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BPHL–CCRCC (OS)

Open the CCRCC breakdown →